{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T22:50:11Z","timestamp":1776293411219,"version":"3.50.1"},"reference-count":8,"publisher":"American Association for Cancer Research (AACR)","issue":"2","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,16]]},"abstract":"<jats:p>Targeted inhibition of mutant BRAF has transformed the management of BRAF-V600\u2013mutant melanoma and other malignancies, with multiple ATP-competitive kinase inhibitors now approved for clinical use. Despite their clinical success, these agents are limited by intrinsic and acquired resistance, paradoxical activation of the MAPK pathway, and dose-limiting toxicities. The development of BRAF-V600X oncoprotein\u2013selective degraders offers a mechanistically distinct therapeutic approach that may bypass several of these liabilities. Thus, the discovery of an orally bioavailable mutant BRAF-selective degrader is highly sought after. In this issue of Cancer Research, Kreger and colleagues developed CFT1946, a clinical-stage, highly potent, RAF family\u2013selective degrader that is effective in various cellular and xenograft models. Importantly, CFT1946 is active in the privileged central nervous system environment, accessing a common site of metastasis for BRAF-mutant melanomas. By eliminating the BRAF-V600X oncoprotein, CFT1946 can overcome RAF dimer\u2013 and EGFR-driven resistance to standard inhibitors. Although the mechanism of mutant selectivity is unclear, this compound exhibits a promising therapeutic index by sparing wild-type RAF proteins in cells. As CFT1946 progresses through clinical development, the field of oncoprotein-specific degradation will mature.<\/jats:p>\n                  <jats:p>See related article by Kreger et al., p. 438<\/jats:p>","DOI":"10.1158\/0008-5472.can-25-4381","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:06:15Z","timestamp":1768550775000},"page":"289-291","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Overcoming the Limits of Inhibition: Mutant-Selective BRAF Degraders"],"prefix":"10.1158","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7125-5907","authenticated-orcid":false,"given":"Pan-Yu","family":"Chen","sequence":"first","affiliation":[{"name":"Opna Bio, South San Francisco, California."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1824-6194","authenticated-orcid":false,"given":"Gideon","family":"Bollag","sequence":"additional","affiliation":[{"name":"Opna Bio, South San Francisco, California."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"2026011603060513800_bib1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41571-023-00852-0","article-title":"BRAF - a tumour-agnostic drug target with lineage-specific dependencies","volume":"21","author":"Hanrahan","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2026011603060513800_bib2","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41467-021-21159-7","article-title":"Mutant-selective degradation by BRAF-Targeting PROTACs","volume":"12","author":"Alabi","year":"2021","journal-title":"Nat Commun"},{"key":"2026011603060513800_bib3","first-page":"438","article-title":"CFT1946 is an orally available brain-penetrant BRAFV600-mutant degrader that overcomes BRAF inhibitor resistance","volume":"86","author":"Kreger","year":"2026","journal-title":"Cancer Res"},{"key":"2026011603060513800_bib4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic - a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2026011603060513800_bib5","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/s41589-020-0609-7","article-title":"Functional characterization of a PROTAC directed against BRAF mutant V600E","volume":"16","author":"Posternak","year":"2020","journal-title":"Nat Chem Biol"},{"key":"2026011603060513800_bib6","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/cas.15401","article-title":"Development of a potent small-molecule degrader against oncogenic BRAFV600E protein that evades paradoxical MAPK activation","volume":"113","author":"Ohoka","year":"2022","journal-title":"Cancer Sci"},{"key":"2026011603060513800_bib7","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nature14982","article-title":"RAF inhibitors that evade paradoxical MAPK pathway activation","volume":"526","author":"Zhang","year":"2015","journal-title":"Nature"},{"key":"2026011603060513800_bib8","doi-asserted-by":"crossref","first-page":"S490","DOI":"10.1016\/j.annonc.2024.08.679","article-title":"Preliminary results from a phase I study of CFT1946, a novel BIDAC degrader in mutant BRAF V600 solid tumors","volume":"35","author":"Vieito","year":"2024","journal-title":"Ann Oncol"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/2\/289\/3724674\/can-25-4381.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/2\/289\/3724674\/can-25-4381.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T08:06:16Z","timestamp":1768550776000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/86\/2\/289\/771687\/Overcoming-the-Limits-of-Inhibition-Mutant"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":8,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1,16]]},"published-print":{"date-parts":[[2026,1,16]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-25-4381","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]}}}